Clinical Trial Update: Evaluation of the Fixed-dose Combination of Irbesartan/Atorvastatin in Type 2 Diabetic Patients Diagnosed With Hyperlipidemia and Hypertension [Phase 4]

View source ↗

Summary

Phase 4 evaluation of a fixed-dose combination of irbesartan/atorvastatin in type 2 diabetes patients with hyperlipidemia and hypertension has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Type 2 Diabetes Mellitus

Drugs mentioned

• irbesartan/atorvastatin fixed-dose combination (irbesartan/atorvastatin)

Snippet

Sponsor: Sanofi | Conditions: Type 2 Diabetes Mellitus | Phase 4 | Status: COMPLETED